Genetic Counseling

Addressing the Needs of Previvors Struggling to Access Screening and Recommended Interventions

TON - September 2018, Vol 11, No 4 - Genetic Counseling

In 2010, FORCE: Facing Our Risk of Cancer Empowered successfully spearheaded passage of a congressional resolution declaring the first-ever National Hereditary Breast and Ovarian Cancer week.

Variants of Uncertain Significance—Frequently Asked Questions

Cristi Radford, MS, CGC, Michele Gabree, MS, CGC

TON - July 2018, Vol 11, No 3 - Genetic Counseling

Cristi Radford, MS, CGC, and Michele Gabree, MS, CGC, explain what variants of uncertain significance are, and address some of the questions that are frequently asked by providers.

New Criteria for Inherited Prostate Cancer Genetic Testing

Cristi Radford, MS, CGC

TON - March 2018, Vol 11, No 1 - Genetic Counseling, NCCN

Similar to other disease sites, prostate cancer has seen a surge in genetic testing options. To help address the role of genetic testing in prostate cancer disease management, the NCCN Clinical Practice Guidelines in Oncology were updated in February 2018 to include germline recommendations.

Is It Time to Reevaluate Universal Screening Strategies for Lynch Syndrome in Patients Newly Diagnosed with Colorectal Cancer?

Cristi Radford, MS, CGC, Nicole Centers, BSN, RN, OCN, CBCN, CN-BN

TON - September 2017, Vol 10, No 5 - Genetic Counseling

Lynch syndrome is a hereditary cancer syndrome that places individuals at an increased risk for colorectal, endometrial, stomach, ovarian, urothelial, and other cancers.

Survivorship Clinics—A Second Opportunity for Genetic Risk Stratification

Cristi Radford, MS, CGC, Nicole Centers, BSN, RN, OCN, CBCN, CN-BN

TON - July 2017, Vol 10, No 4 - Genetic Counseling

One of the challenges of improving cancer care is the integration of genetic risk assessment into survivorship care.

Therapeutic Implications—The Next Era of Genetic Diagnosis

Cristi Radford, MS, CGC

TON - May 2017, Vol 10, No 3 - Genetic Counseling

PARP inhibitors were the first class of drugs specifically developed to treat BRCA-related tumors by targeting the DNA repair pathway. Although they were developed more than a decade ago, the FDA only granted approval for their clinical use a few years ago.

New Data Suggest the Benefit of Multigene Panel Testing for Patients with Early-Onset Colorectal Cancer

Cristi Radford, MS, CGC

TON - March 2017, Vol 10, No 2 - Genetic Counseling

Screening of colorectal cancer (CRC) tumors for mismatch repair (MMR) deficiency has been shown to increase the identification of patients with Lynch syndrome.

Is It Time to Reconsider Testing Adolescents for Familial BRCA Mutations?

Courtney Lewis, MS, CGC , Cristi Radford, MS, CGC

TON - January 2017, Vol 10, No 1 - Genetic Counseling

Parents with inherited cancer mutations often wonder when to disclose results to their children and what affect it will have on them.

Risk and Management Updates for Inherited Colorectal Cancer

Courtney Lewis, MS, CGC , Cristi Radford, MS, CGC

TON - November 2016, Vol 9, No 6 - Genetic Counseling

Advances in technology and decreased testing costs have led to a rise in the number of genes associated with inherited cancer risk for which testing is clinically available.

Increased Risk for Serous/Serous-like Endometrial Cancer Found in BRCA1 Carriers

Cristi Radford, MS, CGC

TON - September 2016, Vol 9, No 5 - Genetic Counseling

BRCA1 and BRCA2 mutations have been shown to confer an increased risk for ovarian, fallopian tube, and primary perineal cancer. As a result, guidelines recommend bilateral salpingo-oophorectomy (BSO) upon completion of child bearing, and preferably between the ages of 35 and 40 years as a risk-reducing option. However, what has been less clear is the association of uterine cancer with BRCA. The data have been conflicting: some studies have suggested a slight increased risk, but others have not. Therefore, hysterectomy has not been included in national medical management guidelines.

Page 1 of 5
Results 1 - 10 of 42